Dublin, May 24, 2017 -- Research and Markets has announced the addition of the "Social Media in Pharma" report to their offering.
Social media covers a range of different online, interactive sites, such as Facebook and Twitter, and these different platforms have a considerable reach and following, with many sites boasting millions of users and daily visits. Despite the rapidly growing popularity of social media, the pharmaceutical industry has been slow to embrace it, constrained by compliance and regulatory concerns and bound by a traditional reluctance for change.
However, the successes seen in other industries and the increasing use of social media by key customers - in particular patients and physicians - means that the pharmaceutical industry can no longer afford to ignore social media, and several companies have taken the leap with Facebook pages, Twitter accounts, and a YouTube presence.
Social media is constantly evolving and new sites are regularly emerging; however, it is expected that the longer-standing platforms such as Facebook and Twitter will continue to dominate, particularly in relation to the pharmaceutical industry. As such, most pharmaceutical companies are creating social media teams to both manage their online social media presence and ensure a robust strategy that takes advantage of the range of benefits that social media provides.
Social media gives pharmaceutical companies the opportunity to engage directly with patients and physicians and rapidly respond to questions, requests for information, and negative opinions on products. More advanced companies are utilizing social media to understand unmet needs, design clinical programs, and discover thought leaders. However, there is still a note of caution, with compliance being at the forefront of many pharmaceutical companies' minds, and, while the industry is starting to embrace social media and build on the many opportunities that it affords them, without clear finalized regulatory guidance, remaining compliant will continue to be main challenge facing the industry.
Key Topics Covered:
1. Executive Summary
2. Social Media in the Pharmaceutical Industry
- Social media is a relatively new method of communication
- Pharma-specific platforms are growing in popularity
- There is little legislation or regulation around social media for pharma Several pharma companies have pioneered the use of social media Bibliography
3. How is Social Media Being Used?
- Pharmaceutical companies use social media in a range of ways Patients use social media to obtain information and make connections Healthcare providers mainly use social media to stay informed Pharma does not tend to use social media to interact with payers Bibliography
4. The Future for Social Media in Pharma
- How will it evolve?
- Opportunities and challenges for pharmaceutical companies
Companies Mentioned
- YouTube
For more information about this report visit http://www.researchandmarkets.com/research/pfcvxc/social_media_in
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Social Media


China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 



